Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics
Introduction
Epigenetics is the study of the heritable and potentially reversible covalent modifications of DNA and its surrounding proteins. These modifications determine whether the DNA strand is tightly wound in nucleosomal arrays (heterochromatin) and consequently, poorly accessible to transcriptional proteins, or if the DNA strand resides in a more relaxed transcriptionally active state (euchromatin). Epigenetic modifications are demonstrably important in influencing the levels of gene expression and play a pivotal role in phenotypic variations (commonly ascribed to the effects of either quantitative trait loci (QTLs) or the environment). These modifications may also be the basis of complex diseases, especially psychosis (Petronis, 2001). Because epigenetic mechanisms, such as histone acetylation, are modifiable by pharmacological interventions, the therapeutic potential of epigenetic research is profound. Inhibitors of histone deacetylase (HDAC) enzymes are already being considered in the treatment of cancer (Blaheta and Cinatl, 2002), and Valproic acid (Depakote®) is an FDA-approved drug for bipolar disorder with recently discovered HDAC-inhibiting property at clinically relevant plasma levels Gottlicher et al., 2001, Phiel et al., 2001.
The purpose of this review is to (1) describe the essential features of the epigenetic machinery in the context of some recent finding relating to the pathophysiology of schizophrenia; (2) present retinoid transcription factors as an illustrative example of the ligand-activated nuclear receptors (LNR), a pharmacologically accessible superfamily of proteins with profound effects on epigenetic mechanisms; and (3) consider the implications of these systems for the research and development of novel pharmacotherapeutic agents.
Section snippets
Epigenetic control of transcription: a brief review
The “normal” ground state for eukaryotic chromatin is nonpermissive to transcription (Struhl, 1999). However, normal chromatin does allow penetration by a small subset of transcription factors, which in turn induce two types of progression (Struhl, 1999); the restrictive ground state can be modified such that chromatin can enter a highly repressed “silent” state or can be converted to a transcriptionally “competent” state. The main components of this regulatory process will be briefly described
Therapeutic approaches towards chromatin structure
In this genomic era, our ability to manipulate genomic sequences is realistically limited to indirectly targeting proteins, albeit those engaged in the most intimate interaction with the DNA strand. Two such pharmacological opportunities are evident. The first is the targeting of proteins involved in aspects of the epigenetic machinery, i.e., DNA methylation and chromatin modifications. The second is the targeting of ligand-activated nuclear transcription factors. While the first is a powerful
Retinoic acid and retinoic acid receptors
Bioactive “retinoids” such as vitamin A (retinal), beta-carotene, and retinyl are acquired from the environment and ultimately converted to retinoic acids (all-trans-retinoic acid [t-RA] and 9-cis-retinoic acid stereo isomers [9-cis RA]). Two families of nuclear receptors transduce the retinoid signal. Each family is comprised of three individual receptors coded by separate genes (RARα, RARβ, and RARγ, as well as RXRα, RXRβ, and RXRγ). RARs have affinity for either RA isomer while RXRs bind
Conclusion
Our ability to manipulate gene expression for therapeutic objectives will be significantly enhanced by our ability to influence chromatin structure. The resurgence of interest in epigenetics, particularly chromatin as a regulatory protein sheath rather than a passive packaging material, paves the way for a new era of innovative pharmacology. This review addresses two such possibilities, nonspecific HDAC inhibitors with genome-wide influence such as valproic acid, and retinoid receptors with
Acknowledgements
The author gratefully acknowledges the helpful comments of Dr. Erminio Costa and Dr. Dennis Grayson, both of the Department of Psychiatry and College of Medicine, University of Illinois at Chicago.
References (70)
- et al.
The effects of l-methionine (without MAOI) in schizophrenia
J. Psychiatr. Res
(1971) Histone deacetylases transcriptional repression with SINers and NuRDs
Trends Cell Biol
(1999)- et al.
Induction of cell cycle arrest and morphological differentiation by Nurr1 and retinoids in dopamine MN9D cells
J. Biol. Chem
(2001) - et al.
An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression
Neuron
(1998) - et al.
In vivo regulation of precursor cells in the subventricular zone of adult rat brain by thyroid hormone and retinoids
Neurosci. Lett
(2000) Congenital anomalies in relatives of schizophrenic probands may indicate a retinoid pathology
Schizophr. Res
(1996)- et al.
Activation of retinoic acid receptor-dependent transcription by all-trans-retinoic acid metabolites and isomers
J. Biol. Chem
(2002) - et al.
Drug-induced changes in chromatin ultrastructure and nuclear basic proteins of the neutrophils of chronic schizophrenics
Prog. Neuropsychopharmacol
(1978) - et al.
Differential expression of retinoid receptors in the adult mouse central nervous system
Neuroscience
(1999) Forebrain induction, retinoic acid, and vulnerability to schizophrenia: insights from molecular and genetic analysis in developing mice
Biol. Psychiatry
(1999)